Value of diagnostic radioiodine scintigraphy and thyroglobulin measurements after rhTSH injection;Stellenwert der diagnostischen Radioiodtherapie und Thyreoglobulinbestimmung nach rhTSH-Gabe

NuklearMedizin

Volumn 48, Issue 1, 2009, Pages 26-29

  Verburg, F A ^a,d,f   De Keizer, B ^a,d   De Klerk, J M H ^a,e   Lentjes, E G W M ^b,d   Lips, C J M ^c,d   Van Isselt, J W ^a,d  

^a Department of Nuclear Medicine ^*  (Netherlands)

^b Clinical Chemistry and Haematology   (Netherlands)

^c Endocrinology   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e MEANDER MEDICAL CENTER   (Netherlands)

^f UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Differentiated thyroid carcinoma; Rhtsh; Thyroglobulin

Indexed keywords

IODINE 131; RADIOACTIVE IODINE; RECOMBINANT THYROTROPIN; THYROGLOBULIN;

ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; THYROID CARCINOMA; THYROID SCINTISCANNING;

CARCINOMA, PAPILLARY; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; RECOMBINANT PROTEINS; THYROGLOBULIN; THYROID NEOPLASMS; THYROTROPIN; THYROXINE;

EID: 62549159986     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.3413/nukmed-0189     Document Type: Article

References (15)

1. Cooper DS, Doherty GM, Haugen BR et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006; 16: 109-142.
2. Haugen BR, Pacini F, Reiners C et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 1999; 84: 3877-3885.
3. Haugen BR, Ridgway EC, McLaughlin BA et al. Clinical comparison of whole-body radioiodine scan and serum thyroglobulin after stimulation with recombinant human thyrotropin. Thyroid 2002; 12: 37-13.
4. Luster M, Felbinger R, Dietlein M et al. Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothy- roidism and a pharmacoeconomic comparison to recombinant thyrotropin administration. Thyroid 2005; 15: 1147-1155.
5. Mazzaferri EL, Robbins RJ, Spencer CA et al. A consensus report of the role of serum thyroglobu- lin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocri- nol Metab 2003; 88: 1433-1441.
6. Mernagh P, Campbell S, Dietlein M et al. Cost-effectiveness of using recombinant human TSH prior to radioiodine ablation for thyroid cancer, compared with treating patients in a hypothyroid state: the German perspective. Eur J Endocrinol 2006; 155: 405-414.
7. 131I scan and serum thyrotropin and stimulated thyroglobulin values in patients studied twice after injection of recombinant human thyrotropin. Eur J Nucl Med Mol Imaging 2007; 34: 363-367.
8. 131I activities versus untreated patients. J Clin Endocrinol Metab 2001; 86: 4092-4097.
9. Pacini F, Molinaro E, Castagna MG et al. Recombinant human thyrotropin-stimulated serum thy- roglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol and Metab 2003; 88: 3668-3673.
10. Pacini F, Molinaro E, Lippi F et al. Prediction of disease status by recombinant human TSH-stimu- lated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma. J Clin Endocri- nol Metab 2001; 86: 5686-5690.
11. Robbins RJ, Chon JT, Fleisher M et al. Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma? J Clin Endocrinol Metab 2002; 87: 3242-3247.
12. Robbins RJ, Tuttle RM, Sharaf RN et al. Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. J Clin Endocrinol Metab 2001; 86: 619-625.
13. Schlumberger M, Berg G, Cohen O et al. Follow- up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endo- crinol 2004; 150: 105-112.
14. Schroeder PR, Haugen BR, Pacini F et al. A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J Clin Endocrinol Metab 2006; 91: 878-884.
15. Verburg FA, de Keizer B, Lips CJ et al. Prognostic significance of successful ablation with radio- iodine of differentiated thyroid cancer patients. Eur J Endocrinol 2005; 152: 33-37.